Literature DB >> 2367524

Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice.

W Y Chen1, D C Wight, T E Wagner, J J Kopchick.   

Abstract

To determine the importance of the third alpha-helix in bovine growth hormone (bGH) relative to growth-related biological activities, the following experimental approach was used: (i) mutagenesis of helix III of bGH to generate an idealized amphiphilic helix; (ii) in vitro expression analyses of the mutated bGH gene in cultured mouse L cells; (iii) mouse liver membrane binding studies of wild-type and mutated bGH; and (iv) expression of the mutated gene in the transgenic mouse. An altered bGH gene (pBGH10 delta 6-M8) was generated that encodes the following changes: glutamate-117 to leucine, glycine-119 to arginine, and alanine-122 to aspartate. The plasmid pBGH10 delta 6-M8 was shown to be expressed in, and its protein product secreted by, mouse L cells. The altered hormone possessed the same binding affinity to mouse liver membrane preparations as wild-type bGH. Transgenic mice containing the mutated bGH gene, however, showed a significant growth-suppressed phenotype. The degree of suppression was directly related to serum levels of the altered bGH molecule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2367524      PMCID: PMC54261          DOI: 10.1073/pnas.87.13.5061

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  The synthesis and hyperglycaemic activity of the amino acid sequence 172-191 of human growth hormone.

Authors:  J D Wade; C O Pullin; F M Ng; J Bornstein
Journal:  Biochem Biophys Res Commun       Date:  1977-09-23       Impact factor: 3.575

2.  Nucleotide sequence and amplification in bacteria of structural gene for rat growth hormone.

Authors:  P H Seeburg; J Shine; J A Martial; J D Baxter; H M Goodman
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

Review 3.  Neural regulation of growth hormone secretion.

Authors:  J B Martin
Journal:  N Engl J Med       Date:  1973-06-28       Impact factor: 91.245

4.  Acute in vivo effects of growth hormone on protein synthesis in various tissues of hypophysectomized rats and their relationship to the levels of thymidine factor and insulin in the plasma.

Authors:  J L Kostyo; D F Nutting
Journal:  Horm Metab Res       Date:  1973-05       Impact factor: 2.936

5.  Molecular weights of prolactins and pituitary growth hormones estimated by gel filtration.

Authors:  P Andrews
Journal:  Nature       Date:  1966-01-08       Impact factor: 49.962

6.  In vitro metabolic effects of bovine growth hormone fragments in adipose tissue.

Authors:  N I Swislocki; M Sonenberg; N Yamasaki
Journal:  Endocrinology       Date:  1970-11       Impact factor: 4.736

7.  Recombination of the biologically active peptides from a tryptic digest of bovine growth hormone.

Authors:  K Hara; C J Hsu Chen; M Sonenberg
Journal:  Biochemistry       Date:  1978-02-07       Impact factor: 3.162

8.  Effects of the amino-terminal portion of human growth hormone on glucose clearance and metabolism in normal, diabetic, hypophysectomized, and diabetic-hypophysectomized rats.

Authors:  M A Salem
Journal:  Endocrinology       Date:  1988-09       Impact factor: 4.736

9.  Sensitivity of the rat diaphragm to growth hormone. II. Early and late effects of growth hormone on amino acid and pentose uptake.

Authors:  A Hjalmarson; K Ahrén
Journal:  Acta Endocrinol (Copenh)       Date:  1967-10

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  37 in total

Review 1.  Recombinant analogues of prolactin, growth hormone, and placental lactogen: correlations between physical structure, binding characteristics, and activity.

Authors:  A Gertler
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

2.  Biologically inactive growth hormone caused by an amino acid substitution.

Authors:  Y Takahashi; H Shirono; O Arisaka; K Takahashi; T Yagi; J Koga; H Kaji; Y Okimura; H Abe; T Tanaka; K Chihara
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice.

Authors:  S L Asa; K T Coschigano; L Bellush; J J Kopchick; S Ezzat
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 5.  Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models.

Authors:  Darlene E Berryman; Jens Sandahl Christiansen; Gudmundur Johannsson; Michael O Thorner; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2008-08-16       Impact factor: 2.372

Review 6.  Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.

Authors:  Nicholas A Tritos; Beverly M K Biller
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Growth hormone controls lipolysis by regulation of FSP27 expression.

Authors:  Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

Review 8.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

Review 9.  Hormonal control of aging in rodents: the somatotropic axis.

Authors:  Holly M Brown-Borg
Journal:  Mol Cell Endocrinol       Date:  2008-07-11       Impact factor: 4.102

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.